Last reviewed · How we verify
nesiritide, furosemide
Nesiritide is a recombinant B-type natriuretic peptide that promotes vasodilation and sodium excretion, while furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending loop of Henle.
Nesiritide is a recombinant B-type natriuretic peptide that promotes vasodilation and sodium excretion, while furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending loop of Henle. Used for Acute decompensated heart failure with dyspnea at rest or with minimal exertion.
At a glance
| Generic name | nesiritide, furosemide |
|---|---|
| Sponsor | Scios, Inc. |
| Drug class | Natriuretic peptide analog and loop diuretic combination |
| Target | Natriuretic peptide receptor-A (NPR-A) and Na-K-2Cl cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nesiritide binds to natriuretic peptide receptors on vascular smooth muscle and endothelial cells, causing vasodilation and reducing cardiac preload and afterload. Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, promoting diuresis and reducing fluid overload. Together, they work synergistically to reduce pulmonary and systemic congestion in acute decompensated heart failure.
Approved indications
- Acute decompensated heart failure with dyspnea at rest or with minimal exertion
Common side effects
- Hypotension
- Headache
- Dizziness
- Nausea
- Abdominal pain
- Hypokalemia
- Worsening renal function
Key clinical trials
- B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading (NA)
- Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion (PHASE4)
- Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS (PHASE4)
- B-type Natriuretic Peptide for the Management of Weaning (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |